Velcade: Clinical Trials

48 trials of Velcade, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed, 10 active not recruiting, 6 terminated, 6 unknown. 48 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 348Completed 20, Active not recruiting 10, Terminated 6, Unknown 6, Recruiting 5, Not yet recruiting 1
Phase 23Not yet recruiting 1, Terminated 1, Unknown 1

Follow Velcade: new trials by email Literature Review of Velcade trials Research Report on Velcade

Trials (filtered) newest first · largest first

All 48 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma
Phase 2 / Phase 3Not yet recruitingChildren's Oncology Group17082026-08-282026-07-30
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
AZD0120, Daratumumab, Carfilzomib - Relapsed Refractory Multiple Myeloma
Phase 3RecruitingAstraZeneca5082026-02-232026-09-29
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection - AL Amyloidosis
Phase 3RecruitingSWOG Cancer Research Network3382024-07-012026-05-06
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Talquetamab, Pomalidomide, Teclistamab - Multiple Myeloma
Phase 3Active not recruitingJanssen Research & Development, LLC8382024-01-222026-11-03
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Plasma Cell Myeloma
Phase 3RecruitingSWOG Cancer Research Network5102023-10-122026-06-10
CURATE.AI Optimized Modulation for Multiple Myeloma
Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma
Phase 2 / Phase 3UnknownNational University Hospital, Singapore202023-09-102023-09-06
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
Isatuximab, Lenalidomide, Bortezomib - Multiple Myeloma
Phase 3CompletedUniversity of Heidelberg Medical Center5142023-04-142026-02-18
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
mezigdomide, Pomalidomide, Bortezomib - Relapsed or Refractory Multiple Myeloma
Phase 3RecruitingCelgene8102022-09-202026-10-30
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Phase 3RecruitingECOG-ACRIN Cancer Research Group14502021-02-242026-11-16
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
Carfilzomib, Lenalidomide, Dexamethasone - Multiple Myeloma
Phase 3Active not recruitingUniversity of Chicago2502019-05-072026-03-04
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
Daratumumab, Velcade, Lenalidomide - Multiple Myeloma
Phase 3Active not recruitingStichting European Myeloma Network7092018-12-142026-02-10
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma
Phase 3CompletedJanssen Research & Development, LLC3952018-11-062026-11-03
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
Lenalidomide, Bortezomib, Dexamethasone - Multiple Myeloma
Phase 3Active not recruitingUniversity of Heidelberg Medical Center6622018-10-182026-02-03
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
Rituximab, Bortezomib - Immune Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic
Phase 3UnknownShandong University2002018-03-012018-02-23
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Daratumumab, Velcade, Dexamethasone - Multiple Myeloma
Phase 3CompletedJanssen Research & Development, LLC2132017-11-302024-05-29
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Velcade, Melphalan, Prednisone - Multiple Myeloma
Phase 3CompletedJanssen Research & Development, LLC2202017-11-232024-04-25
Bortezomib in Intrahepatic Cholangiocellular Carcinoma
Bortezomib - Intrahepatic Cholangiocarcinoma
Phase 3UnknownZhengang Yuan502017-01-012017-11-17
Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
Bortezomib, Dexamethasone - Multiple Myeloma
Phase 3CompletedJanssen Research & Development, LLC812016-09-272019-11-08
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
Venetoclax, Bortezomib, Dexamethasone - Relapsed/Refractory Multiple Myeloma
Phase 3CompletedAbbVie2912016-07-112023-08-22
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
elotuzumab, Lenalidomide, Bortezomib - Multiple Myeloma
Phase 3CompletedUniversity of Heidelberg Medical Center5642015-06-012021-09-10

Showing 20 of 48. Sign in to see all of them.

Conditions studied

Multiple Myeloma (38)  ·  Immunoglobulin Light-chain Amyloidosis (3)  ·  Immunoproliferative Disorders (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms, Plasma Cell (2)  ·  Paraproteinemias (2)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Recurrence (2)  ·  Amyloidosis (1)  ·  Blood Protein Disorders (1)  ·  Cardiovascular Diseases (1)  ·  Cholangiocarcinoma (1)  ·  Hematologic Diseases (1)  ·  Hemorrhagic Disorders (1)

Sponsors

Janssen Research & Development, LLC (7)  ·  National Cancer Institute (NCI) (4)  ·  University of Arkansas (4)  ·  University of Heidelberg Medical Center (3)  ·  Celgene (2)  ·  ECOG-ACRIN Cancer Research Group (2)  ·  SWOG Cancer Research Network (2)  ·  AB Science (1)  ·  AbbVie (1)  ·  Amgen (1)  ·  Asan Medical Center (1)  ·  AstraZeneca (1)  ·  Boston Medical Center (1)  ·  Children's Oncology Group (1)  ·  Fondazione EMN Italy Onlus (1)

Countries

United States (28)  ·  Germany (12)  ·  China (11)  ·  Australia (10)  ·  France (10)  ·  Spain (10)  ·  Canada (9)  ·  Italy (9)  ·  Poland (9)  ·  South Korea (9)  ·  Brazil (8)  ·  Japan (8)  ·  United Kingdom (8)  ·  Czechia (7)  ·  Puerto Rico (7)

Top investigators

Hartmut Goldschmidt, Prof. Dr. (2)  ·  Amine Bensmaine, MD (1)  ·  Andrzej Jakubowiak, MD (1)  ·  Bart Barlogie, MD, PhD (1)  ·  Bertrand Arnulf, MD (1)  ·  Brian M Durie (1)  ·  David T Teachey (1)  ·  Frits van Rhee, MD, PhD (1)  ·  Gareth Morgan, MD, PhD (1)  ·  Hartmut Goldschmidt, Prof. (1)

Results publications

PMID 22689675, PMID 23897961, PMID 34289038, PMID 37990162, PMID 40501401, PMID 19104417, PMID 20807892, PMID 21098740, PMID 21146205, PMID 21228328, PMID 21791469, PMID 21951682, PMID 22498745, PMID 22674807, PMID 23305732, PMID 23603914, PMID 24055414, PMID 24386911, PMID 24449241, PMID 25015938, PMID 26056177, PMID 26671818, PMID 26771810, PMID 27557302, PMID 27829371, PMID 28017406, PMID 28419486, PMID 28586789, PMID 28642620, PMID 29231133, PMID 29567784, PMID 29675792, PMID 30610657, PMID 30626425, PMID 30773463, PMID 30987448, PMID 31097405, PMID 31138244, PMID 31221778, PMID 31221782, PMID 31248973, PMID 31836199, PMID 32029509, PMID 32819447, PMID 32866432, PMID 33006656, PMID 33129376, PMID 33151787, PMID 33242443, PMID 33357481

NIH funding

U10CA180820 (3), U10CA180886 (3), U10CA180888 (3), 2005 (2), 2014 (2), 2015 (2), 2023 (2), U10CA021115 (2), U10CA098543 (2), 2008 (1), 2018 (1), U10CA032102 (1), U24CA196172 (1)